photog
by photog on Thu Aug 20, 2009 12:00 AM
Immunomedics, Inc. announced that the U.S. FDA has allowed its investigational new drug application to initiate Phase I/II clinical trials of doxorubicin conjugate of milatuzumab. The company noted that this is the first antibody-drug conjugate to enter human testing for the treatment of patients with multiple myeloma.
http://myelomic.blogspot.com/2009/08/milatuzumab-doxorubicin
Regards,
Craig
Konner
by Konner on Fri Aug 21, 2009 12:00 AM
When you track a discussion, you will get notified by e-mail if anyone else posts a new message on this discussion. Are you sure you want to track this discussion?
If you stop tracking this discussion, you will no longer get notified by e-mail if anyone else posts a new message on this discussion. Are you sure you want to stop tracking this discussion?
How often do you use a mobile device (e.g., iPhone, Blackberry, etc.) to access the internet?
Every day
A few times a week
Once or twice a month
Never
We care about your feedback. Let us know how we can improve your CancerCompass experience.